“People with bullous pemphigoid live with unrelenting itch, blisters and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late ...

Nemolizumab was well tolerated and provided lasting relief from itching and disease severity while improving quality of life in patients with prurigo nodularis (PN) over 68 weeks. Patients also ...

Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of painful and intensely itchy chronic lesions and blisters, in some cases ...

Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales. The US regulator cleared the IL-31 ...